Drug Profile
Research programme: renin modulators - Medivir
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medivir AB
- Class
- Mechanism of Action Enzyme modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in Sweden
- 12 Jun 2007 Preclinical trials in Hypertension in Sweden (unspecified route)